Clinical trial
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
NCT00424710 · Hawaii Pacific Health, Other · Completed
Key facts
| NCT number | NCT00424710 |
|---|---|
| Title | Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) |
| Official title | Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy (PEARL) |
| Acronym | PEARL |
| Lead sponsor | Hawaii Pacific Health, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Polypoidal Choroidal Vasculopathy |
| Intervention type | Drug |
| Interventions | ranibizumab intravitreal injection |
| Enrollment | 17 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Jan 19, 2007 |
| Last update posted | Nov 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: